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Abstract The purpose of this research study was evalu-
ation of the utility of two common multivariate techniques,
agglomerative cluster analysis (CA) and principal compo-
nent analysis (PCA), as supplementary means of detecting
incompatibilities, which can occur between active phar-
maceutical ingredients and excipients at the preformulation
stage of a solid dosage form. For the detection of incom-
patibilities between atenolol (beta blocker) and selected
excipients (mannitol, lactose, starch, methylcellulose,
b-cyclodextrin, meglumine, chitosan, polyvinylpyrrolidone
and magnesium stearate), the thermogravimetry (TG), dif-
ferential scanning calorimetry (DSC) and Fourier transform
infrared spectroscopy (FTIR) were chosen. The results
have shown that compatibility between atenolol and an
excipient can be identified in a CA dendrogram by two
large clusters, from which one groups an excipient and
physical mixtures with a high concentration of the excipi-
ent. Another cluster encompasses atenolol and mixtures
with a high content of the drug. In the PCA plot, all
samples are located along the first principal component
axis (PC1), beginning from a single component located
with the most negative PC1 value, through mixtures with
gradually varying concentration of both ingredients, till the
second component located close to the most positive PC1
values. The results have shown that CA and PCA fulfil
their role as supporting techniques in the interpretation of
the data acquired from the TG curves, and the obtained
data are compatible with the results of DSC and FTIR
analyses.
Keywords Atenolol  Excipients  Incompatibilities 
TG  DSC  FTIR  Cluster analysis  Principal
component analysis
Introduction
In the preformulation study of solid dosage forms (tablets,
capsules, granules or powders) one major concern is
whether the active pharmaceutical ingredient (API) will be
compatible with any of the excipients, or in the case of
combination drug products whether APIs are compatible
with each other [1, 2]. Incompatibility might lead to
accelerated potency loss, complex formation, acid/base
interactions or eutectic formation. These different modes of
incompatibility might have differing significance resulting
in product’s poor stability or altered bioavailability.
For the rapid and accurate evaluation of the possible
compatibility of APIs with excipients and therefore selecting
excipients with suitable compatibility, a variety of techniques
have been used, including thermal methods of analysis, i.e.,
differential scanning calorimetry (DSC), differential thermal
analysis (DTA), and thermogravimetry (TG) as well as hot
stage microscopy (HSM), Fourier transform infrared spec-
troscopy (FTIR), X-ray powder diffraction (XRPD), and
scanning electron microscopy (SEM) [3–7]. Among these
techniques, thermoanalytical methods have been increasingly
used for evaluating compatibility through comparison of
thermal curves of API alone with those of physical mixtures
containing API and excipients. In general, evaluations and
conclusions are made on the basis of the modifications
observed in thermal curves of API in the absence and in the
presence of excipient.
Recently, new techniques related to methods of thermal
analysis have been introduced to study preformulation
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stage in the solid dosage form development. These are
isothermal microcalorimetry [8, 9], high-sensitivity DSC
(HSDSC) [10] and micro-thermal analysis [11, 12]. These
advanced analytical methodologies are useful for the
investigation of compatibility, but they have also some
limitations, among others, they are expensive and are not
widespread in pharmaceutical laboratories. On the other
hand, a literature survey suggests that DSC is the most
widely used thermal method for the compatibility testing.
In this case, interactions between API and excipients are
deduced from DSC scans by observing changes in thermal
events, such as elimination of an endothermic or exother-
mic peak, appearance of a new peak, changes in the peak,
peak onset or peak maximum temperature, changes in the
peak height-to-width ratio and relative peak height [13]. In
contrast to DSC, the TG technique shows only percentage
mass loss against temperature, and therefore it has a limited
use in the compatibility study [14].
Taking into consideration the fact that TG offers sig-
nificant advantages in saving both time and substance and
enables investigations directly on physical mixtures, it
seemed desirable to elaborate an approach ensuring a more
effective interpretation of the TG data that can be used for
the detection of compatibility/incompatibility directly from
a TG curve. For this reason, the aim of this research study
was evaluation of the utility of two of the most popular
chemometric methodologies, agglomerative cluster analy-
sis (CA) and principal component analysis (PCA), as the
supporting techniques for the detection of incompatibilities
which can occur at the preformulation stage of a solid
dosage form. The basis for chemometric calculations were
data sets obtained from TG analysis of binary physical
mixtures of atenolol with the excipients commonly used in
solid drug technology. DSC and FT-IR analyses were used
for verification of the results.
Atenolol was chosen for the study because it is usually
administered in the form of tablets containing 20, 50 or
100 mg of drug. The systematic name of the drug is (RS)-2-
{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acet-
amide and its chemical formula is presented in Fig. 1.
Atenolol is the most widely used selective b1 receptor
antagonist (beta blocker) that is devoid of intrinsic sym-
pathomimetic and membrane stabilizing activity [15, 16].
The drug can be used to treat hypertension, coronary heart
disease, arrhythmias and angina pectoris, and to treat or
reduce the risk of heart complications following myocar-
dial infarction. It is also used to treat Graves disease until
anti-thyroid medication can take effect. Atenolol is not
extensively metabolized and is excreted primarily in the
urine with a half-life of 6 h, therefore it is usually dosed
once daily.
As the inactive ingredients for the compatibility inves-
tigation, the excipients commonly used in the technology
of solid dosage forms were chosen, such as lactose, starch,
mannitol and chitosan (fillers), starch, methylcellulose,
chitosan and polyvinylpyrrolidone (hydrophilic agents with
binding properties and disintegrants), b-cyclodextrin and
meglumine (stabilisers and diluents), and magnesium
stearate (lubricant and antiadherent) [17]. Starch is also
used in the pharmaceutical technology to preserve humid-
ity and enhance flow and lubricity.
Experimental
Materials
Atenolol was supplied by Polpharma (Starogard Gdanski,
Poland). Mannitol and starch were purchased from POCh
(Gliwice, Poland). Lactose was provided by BUFA BV
(Uitgeest, The Netherlands), whereas methylcellulose was
obtained from the Shin-Etsu Chemical Co. (Tokyo, Japan).
b-Cyclodextrin, meglumine, chitosan and polyvinylpyr-
rolidone were purchased from Fluka (Siegen, Germany),
while magnesium stearate was donated by Faci (Carasco
Genoa, Italy). All substances used in the study were of
pharmacopoeial purity and were used without further
purification.
Methods
The binary physical mixtures of atenolol and excipients
(at the molar or mass ratios of 9:1, 7:3, 1:1, 3:7, 1:9) were
prepared by mixing sufficient amounts of both substances
in a porcelain mortar. Ingredients with similar molar
masses were mixed in molar ratios (atenolol with mannitol,
lactose, meglumine, chitosan and magnesium stearate),
whereas those differing significantly in molar masses were
mixed in mass ratios (atenolol with starch, methylcellulose,
polyvinylpyrrolidone and b-cyclodextrin).
Thermogravimetry, derivative TG (DTG) and DTA
curves of the thermal decomposition of atenolol and




Fig. 1 Structural formula of atenolol
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were obtained using a model OD-103 derivatograph
(MOM, Budapest, Hungary). Samples (200 mg) were placed
in four flat-bottomed platinum pans and heated in the air at a
rate of 5 C min-1 up to a final temperature of 700 C.
a-Al2O3 was employed as a reference material. Each mea-
surement was repeated at least in triplicate.
Differential scanning calorimetry scans of the analysed
samples were carried out on a heat-flux DSC, model 822e
(Mettler Toledo, Schwerzenbach, Switzerland) instrument,
with a liquid nitrogen cooling system (Dewar vessel) and a
STARe software. Samples under study, of approx. 4–5 mg
were accurately weighed (±0.01 mg) and encapsulated in a
40 lL flat-bottomed aluminium pans with crimped-on lids.
Measurements in triplicate were performed over the temper-
ature range of 20–300 C at a heating rate of 10 C min-1
under nitrogen stream at a flux rate of 70 mL min-1.
Indium (In) and zinc (Zn) standards were used to calibrate
the DSC cell. Reference values for onset temperature
and heat flow were as follows: 156.6 C and 28.45 J g-1
(In); 419.6 C and 107.5 J g-1 (Zn), whereas the mea-
sured ones: 156.6 C and 28.80 J g-1 (In); 420.1 C and
110.7 J g-1 (Zn).
The FTIR spectra were recorded on a Nicolet 380 FTIR
spectrometer (Thermo Fischer Scientific, Madison, USA),
with a DTGS KBr detector and an OMNIC software. The
analysed samples were prepared as KBr pellets with the aid
of a hydraulic press (Specac, Orpington, UK). Each pellet
was prepared from a 1 mg sample and 100 mg of a spec-
troscopy-grade KBr (Merck, Darmstadt, Germany). Each
measurement, at least in triplicate, was performed in the
4,000–400 cm-1 spectral region with spectral resolution
of 4 cm-1. Before each measurement, background spectra
was taken with average 16 scans.
Software and calculations
Two unsupervised pattern-recognition techniques, agglom-
erative CA and PCA were used [18, 19]. All statistical
calculations were done using Statistica 7.1 (StatSoft,
Cracow, Poland) software.
The starting point for all calculations was a matrix of the
data with dimensions n 9 p, where n is the number of
rows, i.e. atenolol, excipient and five mixtures of both
ingredients at the molar or mass ratios of 9:1, 7:3, 1:1, 3:7,
1:9, and p is the number of variables, i.e. the temperatures
of subsequent mass losses obtained from the TG curves.
The temperatures, which characterize the TG curves up to
50 % of mass loss (up to 235–340 C for the studied
substances) were taken into consideration, and in addition,
two temperatures: for 75 % of mass loss and for final
decomposition occurs over the range of 460–680 C. All
matrices were 7 9 8 in dimension. All dendrograms in CA
were plotted using Ward’s method and the Euclidean
distance was applied as the measure of similarity. The
number of significant clusters was determined using
Sneath’s index criterion, at 2/3 of the maximum distance.
PCA were done by applying correlation matrices and an
algorithm without a rotation of factors was used.
Results and discussion
In order to check the utility of two of the most widely used
multivariate techniques, CA and PCA, as the supplementary
methods for the detection of incompatibilities which can
occur between drugs and excipients at the preformulation
stage of a solid dosage form, atenolol as basic drug and
nine commonly used pharmaceutical excipients (mannitol,
lactose, starch, methylcellulose, b-cyclodextrin, meglu-
mine, chitosan, polyvinylpyrrolidone and magnesium stea-
rate) were chosen. The substances are organic compounds
differing significantly in their chemical constitution and
molecular mass. Carbohydrates are represented by mannitol
(sugar alcohol), lactose (disaccharide), starch and methyl-
cellulose (polysaccharides). b-cyclodextrin is a cyclic,
non-reducible oligosaccharide, formed with molecules of
a-D-glucopyranose, linked by an a-1,4-glycosidic bond.
Meglumine is an N-methyl-D-glucosamine, whereas chito-
san is a polymer of D-glucosamine with N-acetyl-b-gluco-
samine, obtained through a process of partial deacetylation
of chitin derived from crab and shrimp shells. Polyvinyl-
pyrrolidone is a synthetic polymer consisting of a mixture
of linear polymers of 1-ethenyl-2-pyrrolidinone.
Based on the literature [17] and the results of DSC and
TG analyses (Figs. 2, 3), it can be concluded that the
studied substances react differently when heated. Atenolol
melts at 154–158 C, followed by decomposition which
occurs in two stages. The first stage of thermal destruction
beginning about 200 C and is finalised at 390 C. At this
stage, which runs with 65 % loss of mass, partial degra-
dation of atenolol with the formation of intermediate
products of decomposition occurs. The process goes
through two or three unseparable substages and it is diffi-
cult to identify these products owing to multidirectional
course of thermal destruction of organic matter. In the
second stage, the degradation products of this drug are
subjected to final decomposition accompanied by total
combustion of the coked organic residue. This process goes
to an end at 580 C.
Several substances melt over the range of 100–200 C
(mannitol, meglumine and magnesium stearate), others,
such as different forms of hydrous and anhydrous lactose
melt above 200 C, whereas b-cyclodextrin melts practi-
cally at 300 C [17]. Starch, methylcellulose, chitosan and
polyvinylpyrrolidone begin to decompose above 200 C,
leading to charring. The charred residues are burned at
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higher temperatures (500–700 C). Magnesium oxide appears
as the final product of magnesium stearate decomposition
(about 7 %).
In the case of lactose, the process of melting is preceded
by dehydration which is accompanied by a mass loss of
several percent. Starch and b-cyclodextrin also have a mass
loss of a dozen or so percent at the first stage of heating
which is probably due to the release of water chemically
bonded in the molecular structure of the substances. Pro-
cesses such as crystalline transitions, dehydration and
melting which are accompanied by endothermic peaks in
DSC scans, also occur over this temperature range.
The DSC and TG curves of atenolol, excipients and the
mixtures of both ingredients are shown in Figs. 4, 5, 6 and 7.
The DSC curves illustrate the phase transitions that take
place in the mixtures upon heating, whereas the TG curves
reflect the mass losses due to thermal degradation. Physical
mixtures were examined to estimate the changes in physical
and chemical properties of atenolol and excipient over a
temperature range, which were to be reflected by thermal
changes attributable to both ingredients. Each time the
ingredients were compatible, insignificant variations in the
area of DSC peaks and the shape of TG curves only tran-
spired as a result of the atenolol and excipient contents in the
mixture (Figs. 4, 5). Accordingly, an appearance or disap-
pearance of one or more peaks in DSC curves of drug-
excipient mixtures, a broadening and a shift towards lower
temperature of the endothermic DSC peak of atenolol owing
to the melting or any significant deviations of the TG curves
of physical mixtures from the characteristic shape of TG
curves of both ingredients were considered as an interaction
indication. As shown in Figs. 6 and 7, the appearance of the
new endothermic DSC peak about 280 C for the mixtures
of both ingredients and substantial changes in the shape
of the TG curves suggest interaction of atenolol with
b-cyclodextrin.
The variations in the shape of TG curves, which are
considered to be a proof of incompatibility between drug
and excipient, are not as distinctive as those in DSC scans
(no peaks appeared or disappeared like in the case of DSC
curve). It can be explained by the fact that TG curves
reflect the mass losses which accompany phase transitions
(e.g. sublimation and evaporation) and thermal reactions
which take place in the analysed ingredients and mixtures.
Hence, from the practical point of view, it was not possible
to directly confirm from the subsequent mass losses in the
TG curve if both ingredients of physical mixture are























Fig. 2 DSC scans of active pharmaceutical ingredient a atenolol
and excipients b mannitol, c lactose, d starch, e methylcellulose,





















Fig. 3 TG curves of active pharmaceutical ingredient a atenolol
and excipients b mannitol, c lactose, d starch, e methylcellulose,
f b-cyclodextrin, g meglumine, h chitosan, i polyvinylpyrrolidone and
j magnesium stearate


















Fig. 4 DSC scans of atenolol (a) and chitosan (g) and their physical
mixtures mixed in the molar ratios of 9:1 (b), 7:3 (c), 1:1 (d), 3:7 (e),
1:9 (f)
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use two pattern-recognition methods, CA and PCA, for the
interpretation of these data to acquire as much information
as possible from the TG curves [18, 19]. This advanced
statistical methodology was used to compare the data
obtained from the TG curves and to assess the difference
between them as a way towards identifying the compati-
bilities or incompatibilities of atenolol with excipients.
A graphical illustration of the results of CA and PCA
calculations for the selected mixtures is presented in
Figs. 8 and 9. In the CA dendrogram (Fig. 8a), the com-
patibility of ingredients is identified by two large clusters at
66 % of the maximum distance, from which one groups the
excipient (chitosan) and physical mixtures with a high
excipient concentration (mainly with the ratio of drug to
various excipients of 1:9, 3:7, also 1:1, and sometimes even
7:3). Another cluster encompasses atenolol and mixtures
with a high content of the drug (often with drug-excipient
ratio of 9:1, 7:3 and also 1:1). Such an organisation of the
clusters indicates a close similarity in the thermal decom-
position of a mixture to that of the main ingredient (drug or
excipient). This excludes incompatibilities between the
mixture’s ingredients, the effect of which would be appear-
ance of new mass losses in the TG curves.
The variances and eigenvalues calculated by PCA for
the studied matrices are compiled in Table 1. These values
show that the first principal component (PC1) explains
from 54 to 77 % of the variability studied, and the other
(PC2) from 14 to 37 %. The third principal component
(PC3) encompasses only the range of 4–12 % of the vari-
ability studied, therefore it could be disregarded in the
graphical presentation of the data. Thus, the PCA results
are best visualized in a two-dimensional plot, PC1 versus
PC2, in which both ingredients alone and physical mixtures
create clear clusters.
The score plot presented in Fig. 8b indicates that all
samples are located along the PC1 axis, beginning from the
first ingredient (atenolol) alone, located with the most
negative value of PC1, through the mixtures with a grad-
ually diminishing concentration of the first ingredient and
increasing content of the other, till the second ingredient
(chitosan) located close to the most positive values of PC1.
Such a gradation of thermal properties in the samples
indicated that between the drug and excipient no reaction
took place which could have changed the shape of the TG
curves. It can also be noticed that when both components
are compatible, their mixtures lie on the line that connects
the pure components on the score plot.
The CA and PCA diagrams in the case of anticipated
incompatibilities between atenolol and the analysed
excipients are different as compared to those obtained
when the components are compatible. As illustrated in
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Fig. 5 TG curves of atenolol (a) and chitosan (g) and their physical
mixtures mixed in the molar ratios of 9:1 (b), 7:3 (c), 1:1 (d), 3:7 (e),
1:9 (f)


















Fig. 6 DSC scans of atenolol (a) and b-cyclodextrin (g) and their
physical mixtures mixed in the molar ratios of 9:1 (b), 7:3 (c), 1:1 (d),
3:7 (e), 1:9 (f)
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Fig. 7 TG curves of atenolol (a) and b-cyclodextrin (g) and their
physical mixtures mixed in the molar ratios of 9:1 (b), 7:3 (c), 1:1 (d),
3:7 (e), 1:9 (f)
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Fig. 9a, two large clusters are identified at 66 % of the
maximum distance, one cluster is formed with the excipi-
ent (b-cyclodextrin) and its physical mixtures, and the
other is the atenolol alone. There is also a second possi-
bility in the case of other excipients: one cluster is formed
with the drug and the physical mixtures, and the other
group is the excipient alone. The PCA score plot presented
in Fig. 9b confirms a conclusion derived from CA calcu-
lations. There are two separate clusters, one groups
b-cyclodextrin and its physical mixtures, and the other
atenolol alone. This indicates incompatibility between the
components.
An interesting results were obtained for the mixtures
containing atenolol and polyvinylpyrrolidone. Inspection
of the DSC curves of their mixtures shows that the melting
peaks of atenolol are broader than those of the drug alone
and are significantly shifted to the lower temperatures. This
suggests the incompatibility between the drug and excipi-
ent as confirmed by the literature [20, 21]. On the other
hand, the shape of TG curves varied proportionally to the
atenolol content in the mixture, therefore no interaction
could be expected. Furthermore, XRPD patterns showed
that in the mixtures with a higher amount of the polyvi-
nylpyrrolidone no diffraction peaks were detected sug-
gesting that atenolol was in the amorphous state [21, 22].
The difference in the interpretation of DSC and TG data
lies in the fact that DSC scan shows the phase transitions
(crystalline atenolol converts to the amorphous phase), but
TG curve reflects thermal decomposition of the drug (it is
impossible to distinguish between the decomposition of the
crystalline and amorphous atenolol). For this reason, based
on the TG data, the CA and PCA diagrams correctly show
that atenolol and polyvinylpyrrolidone are compatible.
A comparison of the results obtained by multivariate
methods with those produced by the classical interpretation
of the TG and DSC curves and FTIR spectra to detect
compatibilities or incompatibilities between the ingredi-
ents, is presented in Table 2. The data show that with the
exception of mannitol, lactose, b-cyclodextrin and polyvi-
nylpyrrolidone, the presence of other excipients in the
mixtures with atenolol did not give rise to incompatibili-
ties. These findings are confirmed by the literature. In
the studies with the use of thermal analysis, XRPD and
IR-spectroscopy, the incompatibilities were found between








































Fig. 8 CA dendrogram (a) and PCA score plot (b) for atenolol (At),
chitosan (Ch) and their physical mixtures mixed in the molar ratios of:




































Fig. 9 CA dendorgram (a) and PCA score plot for (b) for atenolol
(At), b-cyclodextrin (Cy) and their physical mixtures mixed in the
mass ratios of: 9:1, 7:3, 1:1, 3:7, 1:9
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[23], probably due to a possible hydrogen-bond formation
by the amine group of atenolol and –OH [24] or C–H and
CH2 [25] groups of mannitol), lactose (decomposition
owing to a Maillard reaction takes place between both
ingredients [20, 26]), b-cyclodextrin (formation of an
inclusion complex in the solid-state) [27] and polyvinyl-
pyrrolidone (strong interaction in the excipient-rich mix-
tures owing to an amorphisation of atenolol) [20–22].
In the accessible data no information was found
concerning the application of mannitol, methylcellulose,
b-cyclodextrin, meglumine and chitosan to manufacture
commercial drug formulations with atenolol. However, the
results of this study indicate that incompatibilities between
mannitol and b-cyclodextrin with atenolol occur, whereas
in the case of methylcellulose, meglumine and chitosan, the
multivariate, DSC, TG and FTIR analyses show that the
ingredients of the mixtures are compatible. This means that
the components listed above were not used as excipients in
the pharmaceutical technology of the atenolol tablets for
other reasons than incompatibility.
In pharmacies there are numerous commercial pharma-
ceutical preparations containing atenolol and excipients,
e.g. starch, polyvinylpyrrolidone and magnesium stearate
are found in Atenolol tablets (Caraco Pharmaceutical
Laboratories, Ltd.); starch and magnesium stearate are
components of the tablets of Atenolol (Ranbaxy Pharma-
ceuticals Inc.), Atenolol (Rebel Distributors Corp.) and
Atenolol (State of Florida DOH Central Pharmacy); mag-
nesium stearate occurs in the tablets of Atenolol and
Chlorthalidone (Mylan Pharmaceuticals Inc.), Atenolol
(Sandoz Inc.) and Normocard (Polfa Warszawa). Further-
more, all other commercial tablets listed in Table 3 contain
polyvinylpyrrolidone and magnesium stearate despite of
the fact that polyvinylpyrrolidone is incompatible with
atenolol [20–22]. However, this interaction is profitable
because it improves the dissolution rate of the poorly
Table 1 Results of PCA calculations for the physical mixtures of atenolol with excipients
Excipient Principal components
PC1 PC2 PC3
Variance/% Eigenvalue Variance/% Eigenvalue Variance/% Eigenvalue
(cumulative variance/%) (cumulative variance/%)
Mannitol 54.8 4.4 37.1 (91.8) 3.0 5.8 (97.6) 0.5
Lactose 69.5 5.6 22.9 (92.3) 1.8 6.5 (98.8) 0.5
Starch 77.6 6.2 11.8 (89.4) 0.9 9.2 (98.6) 0.7
Methylcellulose 62.2 5.0 31.1 (93.4) 2.5 4.2 (97.5) 0.3
b-cyclodextrin 68.0 5.4 20.9 (88.9) 1.7 6.3 (95.2) 0.5
Meglumine 72.6 5.8 19.8 (92.4) 1.6 6.1 (98.5) 0.5
Chitosan 74.8 6.0 15.7 (90.5) 1.3 5.5 (96.0) 0.4
Polyvinylpyrrolidone 73.3 5.9 14.5 (87.8) 1.2 6.4 (94.2) 0.5
Magnesium stearate 54.2 4.3 23.4 (77.6) 1.9 12.0 (89.7) 1.0
Table 2 Incompatibilities between atenolol and excipients based on thermal and multivariate analyses as well as FTIR spectroscopic data.
The ingredients of mixtures are either compatible (?) or incompatible (-)
Excipient TG Multivariate analysis DSC FTIR Ref.
CA PCA
Mannitol ? ? ? - ? [23]
Lactose - - - - ? [20]
Starch ? ? ? ? ? [20]
Methylcellulose ? ? ? ? ?
b-cyclodextrin - - - - - [27]
Meglumine ? ? ? ? ?
Chitosan ? ? ? ? ?
Polyvinylpyrrolidone ? ? ? - ? [20–22]
Magnesium stearate ? ? ? ? ? [20, 28, 29]
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water-soluble atenolol. The use of these excipients in the
pharmaceutical technology of solid dosage forms is con-
sistent with the results of this study.
Conclusions
The performed study on the compatibility or incompatibility
of atenolol with selected excipients (mannitol, lactose,
starch, methylcellulose, b-cyclodextrin, meglumine, chito-
san, polyvinylpyrrolidone and magnesium stearate) has
shown that CA and PCA techniques fulfil their role as sup-
plementary tools in the interpretation of the data obtained
using TG analysis. Based on these multivariate methods it is
possible to detect the compatibilities or incompatibilities
between atenolol and various excipients. These findings are
consistent with the results of DSC and FTIR analyses and
have found confirmation in the literature.
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